The effect of banning MDPV on the incidence of MDPV-positive findings among users of illegal drugs and on court decisions in traffic cases in Finland

International Journal of Legal Medicine

Volumn 129, Issue 4, 2015, Pages 741-749

  Kriikku, Pirkko ^a,b   Rintatalo, Janne ^c   Pihlainen, Katja ^d   Hurme, Jukka ^b   Ojanperä, Ilkka ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Vita Laboratory   (Finland)

^c National Bureau of Investigation Finland   (Finland)

^d Finnish Medicines Agency   (Finland)

Author keywords

Designer drugs; Driving; DUID; MDPV; NPS; Post mortem

Indexed keywords

1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; DESIGNER DRUG; PSYCHOTROPIC AGENT; PYRROLIDINE DERIVATIVE; STREET DRUG;

ADULT; BLOOD; DRUNKEN DRIVING; FEMALE; FINLAND; HUMAN; LEGISLATION AND JURISPRUDENCE; MALE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; SUICIDE; YOUNG ADULT;

ADULT; BENZODIOXOLES; DESIGNER DRUGS; DRIVING UNDER THE INFLUENCE; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; PYRROLIDINES; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; SUICIDE; YOUNG ADULT;

EID: 84931562693     PISSN: 09379827     EISSN: 14371596     Source Type: Journal    
DOI: 10.1007/s00414-015-1184-4     Document Type: Article

References (35)

1. Carroll F, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA (2012) Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci 1248:18–38
2. Hill SL, Thomas SH (2011) Clinical toxicology of newer recreational drugs. Clin Toxicol 49:705–719
3. Kainulainen H, Pihlainen K, Kotovirta E (2014) Muuntohuumeiden valvonta. Yhteiskuntapolitiikka 4, (Control of new psychoactive substances), https://www.julkari.fi/bitstream/handle/10024/116696/kainulainen.pdf?sequence=1 (in Finnish) (accessed 17 Sept 2014).
4. Kavanagh PV, Power JD (2014) New psychoactive substances legislation in Ireland—perspectives from academia. Drug Test Anal 6(7–8):884–891
5. O’Byrne PM, Kavanagh PV, McNamara SM, Stokes SM (2013) Screening of stimulants including designer drugs in urine using a liquid chromatography tandem mass spectrometry system. J Anal Toxicol 37:64–73
6. Duffert A (2014) Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective. Drug Test Anal 6(7–8):876–878
7. Kikura-Hanajiri R, Kawamura NUM, Goda Y (2013) Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test Anal 6(7–8):832–839
8. Winstock A, Mitcheson L, Marsden J (2010) Mephedrone: still available and twice the price. Lancet 376:1537
9. Freeman TP, Morgan CJ, Vaughn‐Jones J, Hussain N, Karimi K, Curran HV (2012) Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high’. Addiction 107:792–800
10. Wilkins C, Sweetsur P, Parker K (2014) The impact of the prohibition of benzylpiperazine (BZP) “legal highs” on the availability, price and strength of BZP in New Zealand. Drug Alcohol Depend 144:47–52
11. Kriikku P, Wilhelm L, Schwarz O, Rintatalo J (2011) New designer drug of abuse: 3, 4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int 210:195–200
12. Adamowicz P, Gil D, Skulska A, Tokarczyk B (2013) Analysis of MDPV in blood—determination and interpretation. J Anal Toxicol 37:308–312
13. German CL, Fleckenstein AE, Hanson GR (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97:2–8
14. Corkery J, Schifano F, Ghodse AH (2012) Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. In: Gallelli L (ed) Pharmacology. InTech, Rijeka, Croatia, pp 355–380
15. Bretteville-Jensen AL, Tuv SS, Bilgrei OR, Fjeld B, Bachs L (2013) Synthetic cannabinoids and cathinones: prevalence and markets. Forensic Sci Rev 25:7–26
16. Murray BL, Murphy CM, Beuhler MC (2012) Death following recreational use of designer drug "bath salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 8:69–75
17. Coppola M, Mondola R (2012) 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12–15
18. Ross EA (2012) Psychoactive “bath salts” intoxication with methylenedioxypyrovalerone. Am J Med 125:854–858
19. Wyman JF, Lavins ES, Engelhart D, Armstrong EJ, Snell KD, Boggs PD, Miller FP (2013) Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts”. J Anal Toxicol 37:182–185
20. Elliott S, Evans J (2014) A 3 year review of new psychoactive substances in casework. Forensic Sci Int 243:55–60
21. Wright TH, Cline-Parhamovich K, Lajoie D, Parsons L, Dunn M, Ferslew KE (2013) Deaths involving methylenedioxypyrovalerone (MDPV) in upper east Tennessee. J Forensic Sci 58:1558–1562
22. Spiller HA, Ryan ML, Weston RG et al (2011) Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 49:499–505
23. Antonowicz JL, Metzger AK, Ramanujam SL (2011) Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 33:640
24. Spencer JW, Long C, Scalzo AJ et al (2011) Acute psychiatric, cardiopulmonary, and neurologic effects of laboratory-confirmed use of methylenedioxypyrovalerone (MDPV) “bath salts”. Clin Toxicol 49:515–627
25. Thornton SL, Gerona RR, Tomaszewski CA (2012) Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 8:310–313
26. Silber BY, Croft RJ, Papafotiou K, Stough C (2006) The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology 187:154–169
27. Logan BK, Couper FJ (2001) 3, 4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment. J Forensic Sci 46:1426–1433
28. Häkkinen M, Launiainen T, Vuori E, Ojanperä I (2012) Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol 68:301–309
29. Ojanperä IA, Heikman PK, Rasanen IJ (2011) Urine analysis of 3, 4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography–mass spectrometry. Ther Drug Monit 33:257–263
30. Simonsen KW, Normann PT, Ceder G, Vuori E, Thordardottir S, Thelander G, Hansen AC, Teige B, Rollmann D (2011) Fatal poisoning in drug addicts in the Nordic countries in 2007. Forensic Sci Int 207:170–176
31. Simonsen KW, Edvardsen HM, Thelander G, Ojanperä IA, Thordardottir S, Andersen LV, Kriikku P, Vindenes V, Christoffersen D, Møller Delaveris GJ, Frost J (2014) Fatal poisoning in drug addicts in the Nordic countries in 2012, Poster presented in the 52nd annual meeting of the international association of forensic toxicologist (TIAFT). Buenos Aires, Argentina
32. Ojaniemi KK, Lintonen TP, Impinen AO, Lillsunde PM, Ostamo AI (2009) Trends in driving under the influence of drugs: a register-based study of DUID suspects during 1977–2007. Accid Anal Prev 41:191–196
33. Roy A (2003) Characteristics of drug addicts who attempt suicide. Psychiat Res 121:99–103
34. Lynch WJ, Roth ME, Carroll ME (2002) Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology 164:121–137
35. Musshoff F, Madea B (2012) Driving under the influence of amphetamine‐like drugs. J Forensic Sci 57:413–419